B. Braun drives innovation in health care while sales and profit improved

“As a family-owned company with 63,000 committed employees, B. Braun has shown that we know how to navigate through volatile times. In a demanding environment, we have been able to stay on our path of growth thanks to our versatile expertise, our portfolio, and the possibilities of new technology. At the same time, we supported our customers with innovative solutions for better health care,” said Chief Executive Officer Anna Maria Braun today at B. Braun SE's online financial statement press conference.

The B. Braun Group’s wide international presence and portfolio have had a positive impact on the medical technology company’s sales. Hospital Care saw growth driven mainly by IV solutions, single-use products for automated infusion systems, IV sets and accessories as well as IV catheters and regional anesthesia products. The Aesculap division grew strongly, especially in instruments, hip and knee implants, imaging systems and suture materials. Avitum generated sales growth in extracorporeal blood therapy products as well as in wound and ostomy care products and renal care centers, where patient numbers reached the previous year’s level at over 27,000. Sales of PPE and gloves declined following the end of the coronavirus pandemic. B. Braun saw growth in nearly every one of its sales regions.

The B. Braun Group’s profit position improved from the previous year: profit before tax came in at 206.0 million euros, 15.3 percent higher than the previous year’s amount (178.7 million euros). This growth can for the most part be attributed to efforts to improve profits that B. Braun successfully implemented worldwide over the last two years. Resources were pooled, and the capacity utilization and specific competencies of locations were reinforced.

With this disciplined and focused approach, B. Braun was able to further its investments in 2023 despite a volatile market environment and various one-off effects: A total of 1.2 billion euros was poured into production capacity, research and development, and new technology. B. Braun’s goal is to use technology such as robotics, artificial intelligence, and automation to make its processes more efficient and make innovation accessible for better health care. The company enhances the benefits of its core medical products with other products, services, and digital systems—examples include the Space^Plus automated infusion pump system, robotic surgery systems in the OR and catheterization laboratory, and the use of artificial intelligence in hemodialysis.
More information at:  
Smart maintenance of dialysis machines: www.bbraun.com/smart-maintenance
Infusion pump system Space^Plus: www.bbraun.com/spaceplus
Robotic surgery system Aesculap Aeos®: www.bbraun.com/aesculapaeos

B. Braun also uses new technology to develop sustainable solutions. In Melsungen, the company began expanding production of dialysis machines and infusion pumps in the 2023 fiscal year. This expansion included the integration of the latest technology into building services and implementation of GHG neutral production for building operations. This includes photovoltaics, energy recovery, regenerative electricity, and heat pumps with an over 1,000 cubic meter underground thermal ice storage facility.     

In addition to how important new technology is to B. Braun, Anna Maria Braun emphasized at today’s press conference that the family-owned company's success depended critically on the commitment and determination of its employees: “Our employees bring their diverse expertise to work every day to help B. Braun, as a true partner, develop smart solutions and set standards for better health care. I sincerely thank them for their motivation, hard work, and willingness to embrace change.” 

More information on B. Braun SE’s business performance can be found in the latest Annual Report at www.bbraun.com/ar2023.